摘要
目的 评价培哚普利氨氯地平片治疗高血压的有效性和安全性。方法 检索建库至2021年8月6日,在中国知网、万方数据库、中国生物医学文献服务系统、Pubmed、The Cochrane Library、EMBASE数据库发表的培哚普利氨氯地平片治疗高血压的随机对照研究。从符合纳入标准的文献中提取数据,采用R软件进行Meta分析。结果 共纳入8项随机对照试验(randomized controlled trial,RCT)研究,包含8910例患者。有效性方面:培哚普利氨氯地平片收缩压降低效果优于培哚普利单方组(MD=5.79,95%CI:3.39~8.18),但与氨氯地平单方组(MD=2.93,95%CI:–0.15~6.01)比较,差异无统计学意义(P>0.05);培哚普利氨氯地平片血压控制达标率优于氨氯地平单方组(RD=0.11,95%CI:0.01~0.21),优于培哚普利单方组(RD=0.26,95%CI:0.20~0.33)。安全性方面:培哚普利氨氯地平片对比氨氯地平单方(RD=–0.00,95%CI:–0.07~0.06)、培哚普利单方(RD=0.03,95%CI:–0.01~0.06)的紧急不良事件的发生率,差异均无统计学意义(P>0.05);培哚普利氨氯地平片对比氨氯地平单方(RD=0.02,95%CI:–0.01~0.05)、培哚普利单方(RD=0.04,95%CI:–0.01~0.08)的咳嗽发生率,差异均无统计学意义(P>0.05);培哚普利氨氯地平片对比氨氯地平单方(RD=–0.02,95%CI:–0.07~0.02)、培哚普利单方(RD=0.02,95%CI:–0.03~0.07)外周水肿的发生率,差异均无统计学意义(P>0.05)。结论 与对照组比较,培哚普利氨氯地平片可显著改善患者血压情况,但安全性比较差异无统计学意义。受纳入研究数量和质量的限制,上述结论尚待更多高质量研究予以验证。
Objective To evaluate the efficacy and safety of perindopril and amlodipine fixed–dose combination for hypertension treatment. Methods China National Knowledge Infrastructure, Wanfang database, China Bio–medicine Database, Pubmed, The Cochrane library and EMBASE database were searched for randomized controlled trials(RCT) that investigated perindopril and amlodipine fixed–dose combination in patientswith hypertension from inception to August 6,2021. R software was used to perform analysis. Results Eight RCTs with a total of 8910 patients were included. Perindopril and amlodipine fixed–dose combination was more effective for reducing systolic blood pressure(SBP) comparing with perindopril [MD=5.79,95% confidence interval(CI): 3.39–8.18];there was no statistically significant difference in the reduction of SBP between perindopril and amlodipine fixed–dose combination group and amlodipine group(MD=2.93,95%CI: –0.15–6.01). BP control rates of the perindopril and amlodipine fixed–dose combination group was significantly greater than amlodipine group(RD=0.11, 95%CI: 0.01–0.21) and perindopril group(RD=0.26, 95%CI: 0.20–0.33). In terms of safety, the emergent adverse events rate of perindopril and amlodipine fixed–dose combination group in the treatment of hypertension was not significantly different from that of amlodipine group(RD=–0.00, 95%CI: –0.07–0.06) and perindopril group(RD=0.03, 95%CI: –0.01–0.06). There was neither statistically significant difference in the cough nor peripheral edema rate comparing perindopril and amlodipine fixed–dose combination group to amlodipine group(RD=0.02,95%CI: –0.01–0.05;RD=–0.02, 95%CI: –0.07–0.02) as well as perindopril group(RD=0.04, 95%CI: –0.01–0.08;RD=0.02,95%CI: –0.03–0.07). Conclusion The effect of perindopril arginine and amlodipine besylate tablets was better than that of the control groups in the treatment of hypertension, and there was no significant difference in safety. Limited by the quantity and quality of inclu
作者
黄果
汪阳
周颖玉
徐英峰
韩晟
HUANG Guo;WANG Yang;ZHOU Yingyu;XU Yingfeng;HAN Sheng(Science and Technology Development Center of Chinese Pharmaceutical Association,Beijing 100022,China;International Research Center for Medicinal Administration,Peking University,Beijing 100191,China;School of Pharmacy,Peking University,Beijing 100191,China)
出处
《中国现代医生》
2022年第24期40-48,共9页
China Modern Doctor
关键词
培哚普利氨氯地平片
高血压
有效性
安全性
META分析
Perindopril arginine and amlodipine besylate tablets
Hypertension
Efficacy
Safety
Meta–analysis